{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:19:46Z","timestamp":1765808386514,"version":"3.40.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.eclinm.2024.102790","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:36:12Z","timestamp":1724409372000},"page":"102790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An evaluation of 2015\u20132019 United States respiratory syncytial virus hospitalizations as a framework to develop potential strategies for the preventiosn of the hospital burden among infants"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0318-5252","authenticated-orcid":false,"given":"Robert J.","family":"Suss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.F.","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2023","series-title":"FDA approves Beyfortus\u2122 (nirsevimab-alip) to protect infants against RSV disease","key":"10.1016\/j.eclinm.2024.102790_bib1"},{"year":"2023","series-title":"FDA approves first vaccine for Pregnant individuals to prevent RSV in infants","key":"10.1016\/j.eclinm.2024.102790_bib2"},{"author":"Kimber","key":"10.1016\/j.eclinm.2024.102790_bib3"},{"year":"2023","series-title":"ABRYSVO (respiratory syncytial virus Stabilized prefusion F subunit vaccine) product monograph product monograph","key":"10.1016\/j.eclinm.2024.102790_bib4"},{"year":"2024","series-title":"(Recombinant respiratory syncytial virus pre-fusion F protein) vaccine","key":"10.1016\/j.eclinm.2024.102790_bib5"},{"issue":"72","key":"10.1016\/j.eclinm.2024.102790_bib6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization Practices \u2014 United States, 2023","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"72","key":"10.1016\/j.eclinm.2024.102790_bib7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102790_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"Supplement_2","key":"10.1016\/j.eclinm.2024.102790_bib9","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/infdis\/jiac211","article-title":"The burden of respiratory syncytial virus lower respiratory tract disease in infants in the United States: a synthesis","volume":"226","author":"Sim\u00f5es","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102790_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102790_bib11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3611","article-title":"Respiratory syncytial virus\u2013associated hospitalizations among young children: 2015\u20132016","volume":"146","author":"Rha","year":"2020","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102790_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102790_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2252289","article-title":"Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration","volume":"19","author":"Packnett","year":"2023","journal-title":"Hum Vaccines Immunother"},{"year":"2023","series-title":"ACIP and AAP recommendations for nirsevimab","key":"10.1016\/j.eclinm.2024.102790_bib15"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102790_bib16","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41467-022-30485-3","article-title":"Off-season RSV epidemics in Australia after easing of COVID-19 restrictions","volume":"13","author":"Eden","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102790_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/INF.0b013e3181a3e5b6","article-title":"Predictors of the duration of the respiratory syncytial virus season","volume":"28","author":"Zachariah","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102790_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7125","article-title":"Respiratory syncytial virus hospital-based burden of disease in children younger than 5 Years, 2015-2022. In press","volume":"7","author":"Suss","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102790_bib19","article-title":"Born too soon: preterm birth matters","volume":"10","author":"Howson","year":"2013","journal-title":"Reprod Health"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102790_bib20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","article-title":"Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants","volume":"29","author":"Wilkins","year":"2023","journal-title":"Nat Med"},{"year":"2024","series-title":"Immunogenicity analysis of a phase 3 maternal RSV preF vaccine clinical trial to protect infants. Presented at: international neonatal and maternal immunization symposium (INMIS)","author":"Kampmann","key":"10.1016\/j.eclinm.2024.102790_bib21"},{"key":"10.1016\/j.eclinm.2024.102790_bib22","first-page":"38","article-title":"Respiratory syncytial virus bivalent stabilized prefusion F subunit vaccine (RSVpreF): VRBPAC briefing document","author":"Pfizer","year":"2023","journal-title":"Food and Drug Administration"},{"year":"2024","series-title":"Protection against infant illness with a bivalent RSVpreF vaccine in pregnancy: final analysis","author":"Iona Munjal","key":"10.1016\/j.eclinm.2024.102790_bib23"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2024.102790_bib24","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","article-title":"Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model","volume":"226","author":"Kieffer","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102790_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-021-00566-9","article-title":"Potential impact of nirsevimab on RSV transmission and medically attended lower respiratory tract illness caused by RSV: a disease transmission model","volume":"11","author":"Voirin","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102790_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102790_bib27","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1017\/S0950268816000352","article-title":"Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010\u20132014: the importance of birth month","volume":"144","author":"Reeves","year":"2016","journal-title":"Epidemiol Infect"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102790_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273962","article-title":"The role of birth month in the burden of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in Croatia","volume":"17","author":"Li","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102790_bib29","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0000000000004173","article-title":"Disagreement FDA and EMA on RSV maternal vaccination: possible consequence for global mortality","volume":"43","author":"Willemsen","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.eclinm.2024.102790_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2021.04.588","article-title":"Cost-effectiveness of nirsevimab against respiratory syncytial VIRUS (RSV) among US infants experiencing their first RSV season","volume":"24","author":"Beuvelet","year":"2021","journal-title":"Value Health"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:56:53Z","timestamp":1727171813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024003699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"alternative-id":["S2589537024003699"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102790","relation":{},"ISSN":["2589-5370"],"issn-type":[{"type":"print","value":"2589-5370"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evaluation of 2015\u20132019 United States respiratory syncytial virus hospitalizations as a framework to develop potential strategies for the preventiosn of the hospital burden among infants","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102790"}}